Christopher Carroll

Christopher Carroll

Auto-generated profile, based on publicly available information

Christopher Carroll

Department of Experimental Medical Science, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Neoplasia
Verified
Journal Article
Open access
CCChristopher Paul Carroll
Christopher Paul Carroll
HBHannah Bolland
Hannah Bolland
EVEric Vancauwenberghe
Eric Vancauwenberghe
PCPamela Collier
Pamela Collier
ARAlison A. Ritchie
Alison A. Ritchie
AMAlan McIntyre
Alan McIntyre
Regions of low oxygen (hypoxia) are found in >50% of breast tumours, most frequently in the more aggressive triple negative breast cancer subtype (TNBC). Metastasis is the cause of 90% of breast cancer patient deaths. Regions of tumour hypoxia tend to be more acidic and both hypoxia and acidosis increase tumour metastasis. In line with this the metastatic process is dependent on pH regulatory mechanisms. We and others have previously identified increased hypoxic expression of Na+ driven bicarbonate transporters (NDBTs) as a major mechanism of tumour pH regulation. Hypoxia induced the expression of NDBTs in TNBC, most frequently SLC4A4 and SLC4A5. NDBT inhibition (S0859) and shRNA knockdown suppressed migration (40% reduction) and invasion (70% reduction) in vitro. Tumour xenograft metastasis in vivo was significantly reduced by NDBT knockdown. To investigate the mechanism by which NDBTs support metastasis, we investigated their role in regulation of phospho-signalling, epithelial-to-mesenchymal transition (EMT) and metabolism. NDBT knockdown resulted in an attenuation in hypoxic phospho-signalling activation; most notably LYN (Y397) reduced by 75%, and LCK (Y394) by 72%. The metastatic process is associated with EMT. We showed that NDBT knockdown inhibited EMT, modulating the expression of key EMT transcription factors and ablating the expression of vimentin whilst increasing the expression of E-cadherin. NDBT knockdown also altered metabolic activity reducing overall ATP and extracellular lactate levels. These results demonstrate that targeting hypoxia-induced NDBT can be used as an approach to modulate phospho-signalling, EMT, and metabolic activity and reduce tumour migration, invasion, and metastasis in vivo.

7 March 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
CCChristopher Carroll
Christopher Carroll
AMAuraya Manaprasertsak
Auraya Manaprasertsak
ACArthur Boffelli Castro
Arthur Boffelli Castro
HBHilda van den Bos
Hilda van den Bos
DSDiana C.J. Spierings
Diana C.J. Spierings
EHEmma U. Hammarlund
Emma U. Hammarlund
Therapeutic resistance and recurrence remain core challenges in cancer therapy. How therapy resistance arises is currently not fully understood with tumors surviving via multiple alternative routes. Here, we demonstrate that a subset of cancer cells survives therapeutic stress by entering a transient state characterized by whole-genome doubling. At the onset of the polyploidization program, we identified an upregulation of key transcriptional regulators, including the early stress-response protein AP-1 and normoxic stabilization of HIF2α. We found altered chromatin accessibility, ablated expression of retinoblastoma protein (RB1), and enrichment of AP-1 motif accessibility. We demonstrate that AP-1 and HIF2α regulate a therapy resilient and survivor phenotype in cancer cells. Consistent with this, genetic or pharmacologic targeting of AP-1 and HIF2α reduced the number of surviving cells following chemotherapy treatment. The role of AP-1 and HIF2α in stress response by polyploidy suggests a novel avenue for tackling chemotherapy-induced resistance in cancer. Significance: In response to cisplatin treatment, some surviving cancer cells undergo whole-genome duplications without mitosis, which represents a mechanism of drug resistance. This study presents mechanistic data to implicate AP-1 and HIF2α signaling in the formation of this surviving cell phenotype. The results open a new avenue for targeting drug-resistant cells.

6 March 2025 in Analytical Methods
Verified
Journal Article
Open access
AMAuraya Manaprasertsak
Auraya Manaprasertsak
RRRobin Rydbergh
Robin Rydbergh
QWQicheng Wu
Qicheng Wu
MSMaria Slyusarenko
Maria Slyusarenko
CCChristopher Carroll
Christopher Carroll
EHEmma U. Hammarlund
Emma U. Hammarlund
This study investigates chemical changes in cancer cells post-treatment, revealing lipid droplet accumulation using ToF-SIMS and multivariate analysis, emphasizing their role in therapeutic resistance and potential as biomarkers.

7 March 2024
Verified
Other
Open access
CCChristopher Carroll
Christopher Carroll
AMAuraya Manaprasertsak
Auraya Manaprasertsak
ACArthur Boffelli Castro
Arthur Boffelli Castro
HBHilda van den Bos
Hilda van den Bos
DSDiana C.J. Spierings
Diana C.J. Spierings
EHEmma U. Hammarlund
Emma U. Hammarlund
Figure S2: Brightfield images of cell lines after treatment with LD50 cisplatin.

7 March 2024
Verified
Other
Open access
CCChristopher Carroll
Christopher Carroll
AMAuraya Manaprasertsak
Auraya Manaprasertsak
ACArthur Boffelli Castro
Arthur Boffelli Castro
HBHilda van den Bos
Hilda van den Bos
DSDiana C.J. Spierings
Diana C.J. Spierings
EHEmma U. Hammarlund
Emma U. Hammarlund
Figure S1: Dose response curves for cell lines after 72h cisplatin treatment

7 March 2024
Verified
Other
Open access
CCChristopher Carroll
Christopher Carroll
AMAuraya Manaprasertsak
Auraya Manaprasertsak
ACArthur Boffelli Castro
Arthur Boffelli Castro
HBHilda van den Bos
Hilda van den Bos
DSDiana C.J. Spierings
Diana C.J. Spierings
EHEmma U. Hammarlund
Emma U. Hammarlund
Figure S3: Cell diameter distributions for cell lines HCC1806, HCT116, and 786-0